| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/(SICI)1099-1654(200001/02)10:1<17::AID-RMV258>3.0.CO;2-G |
| P698 | PubMed publication ID | 10654002 |
| P50 | author | Bernard Roizman | Q4893595 |
| P2093 | author name string | G Y Gillespie | |
| R J Whitley | |||
| R R Weichselbaum | |||
| J M Markert | |||
| P2860 | cites work | Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells | Q24306649 |
| Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery | Q33483488 | ||
| Capsid assembly and DNA packaging in herpes simplex virus | Q33682957 | ||
| Mechanism and application of genetic recombination in herpesviruses | Q33729830 | ||
| The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. | Q34294662 | ||
| Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas | Q34297434 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins | Q34463480 | ||
| Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma | Q34616722 | ||
| Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells | Q34674371 | ||
| Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo | Q35152561 | ||
| Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models | Q35611914 | ||
| Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase | Q35693935 | ||
| Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system | Q36754315 | ||
| Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents | Q36761728 | ||
| Demonstration of the specificity of poliovirus encapsidation using a novel replicon which encodes enzymatically active firefly luciferase | Q38552725 | ||
| Genetics of natural resistance to herpesvirus infections in mice | Q39958787 | ||
| Gene transfer to brain using herpes simplex virus vectors | Q40753488 | ||
| p53-dependent cell death/apoptosis is required for a productive adenovirus infection | Q41009439 | ||
| Liposomal transfection efficiency and toxicity on glioma cell lines: in vitro and in vivo studies | Q41044678 | ||
| Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside | Q41073279 | ||
| Transfection with bFGF sense and antisense cDNA resulting in modification of malignant glioma growth | Q41391689 | ||
| Bystander tumoricidal effect in the treatment of experimental brain tumors | Q41419847 | ||
| Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system | Q41458222 | ||
| An experimental model of retrovirus gene therapy for malignant brain tumors | Q41543855 | ||
| Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir | Q41563446 | ||
| Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir | Q41576545 | ||
| In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors | Q42818740 | ||
| Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors | Q44221281 | ||
| Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture | Q44460699 | ||
| Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine | Q44905114 | ||
| Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats | Q44978458 | ||
| Present status of oncolytic virus studies | Q45717443 | ||
| Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. | Q45780982 | ||
| Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant | Q45854779 | ||
| Spatial and temporal control of gene therapy using ionizing radiation | Q45867429 | ||
| Adenovirus-mediated gene therapy of experimental gliomas | Q45870226 | ||
| Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors | Q45886976 | ||
| Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo | Q45887791 | ||
| Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. | Q48365430 | ||
| Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth | Q48752349 | ||
| A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors | Q48762505 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 17-30 | |
| P577 | publication date | 2000-01-01 | |
| P1433 | published in | Reviews in Medical Virology | Q15766137 |
| P1476 | title | Genetically engineered HSV in the treatment of glioma: a review | |
| P478 | volume | 10 |
| Q34648103 | A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors |
| Q33851852 | A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals |
| Q33587028 | A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. |
| Q45323639 | Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory |
| Q44135421 | Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid |
| Q39953338 | Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. |
| Q35559877 | Design and application of oncolytic HSV vectors for glioblastoma therapy |
| Q35753517 | Development of herpesvirus-based episomally maintained gene delivery vectors |
| Q45738799 | Direct and mononuclear cell mediated effects on interleukin 6 production by glioma cells in infection with herpes simplex virus type 1. |
| Q36659325 | Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus |
| Q45411954 | Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors |
| Q37116149 | Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells |
| Q40464370 | Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. |
| Q40277858 | Entry of herpes simplex virus mediated by chimeric forms of nectin1 retargeted to endosomes or to lipid rafts occurs through acidic endosomes |
| Q40134125 | HSV-1 amplicon-mediated post-transcriptional inhibition of Rad51 sensitizes human glioma cells to ionizing radiation |
| Q42675409 | Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain |
| Q33948597 | Herpes simplex virus infections |
| Q34139375 | Herpes simplex viruses: is a vaccine tenable? |
| Q39442081 | Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection |
| Q35800497 | Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model |
| Q37198935 | Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells |
| Q42353164 | Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer |
| Q53347956 | MTH-68/H oncolytic viral treatment in human high-grade gliomas. |
| Q35545367 | Neonatal herpes simplex infection |
| Q35939662 | Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology |
| Q40788613 | Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. |
| Q35040863 | Oncolytic adenoviruses for treatment of brain tumours |
| Q36326291 | Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review |
| Q35610296 | Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas |
| Q33712977 | Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM |
| Q35943736 | Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12 |
| Q37736499 | RNA interference therapy for glioblastoma |
| Q35939421 | Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma |
| Q37882608 | Rethinking herpes simplex virus: the way to oncolytic agents |
| Q37945174 | Spontaneous and Engineered Compensatory HSV Mutants that Counteract the Host Antiviral PKR Response |
| Q45733718 | The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma |
| Q36990672 | Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery |
Search more.